"Genentech’s research environment empowers experts from diverse fields to collaborate effectively, translating their work into scientific innovations and discoveries that benefit patients."
I joined Genentech in early 2022 as a Principal Scientist in the Proteomic and Genomics Technologies department. My group studies proteins and peptides on the surface of cells using innovative proteomics methodologies. We collaborate across departments in research biology, drug discovery and computational sciences.
Prior to joining Genentech, I trained in Molecular Biotechnology and Proteomics. During my PhD at the Technical University of Munich and the German Cancer Consortium, I applied chemoproteomics approaches to study selectivity of clinical kinase inhibitors. Motivated by the possible translational impact of my research, I joined the Proteomics Platform at the Broad Institute, where I used mass spectrometry-based proteomics to understand antigen processing and presentation on MHC molecules in tumor samples. This research contributed to better MHC binding predictors, discovery of novel peptides from non canonical open reading frames and improvement of technology to detect low abundant, clinically relevant peptides presented on MHC.
Mol Cell Proteomics . 2025
Nat Biotechnol . 2022
Cell. 2021
Nat Biotechnol . 2020
Science . 2017